Clinical Trials Logo

Clinical Trial Summary

Background:

- Thalassemia major (TM) is a chronic disorder that affects a person s ability to produce hemoglobin, resulting in anemia. Hemoglobin is a component of red blood cells that carries oxygen and nutrients to cells in the body. As a result, individuals require life-long blood transfusions and extensive medical management. Studies have shown that because of its demanding nature, TM might negatively affect an individual s quality of life, sense of self, and social integration, but little is known about affected individuals overall experiences with and perceptions of TM.

- TM is caused by a genetic change in the thalassemia gene. The disease is passed to children by parents who carry one copy of the altered thalassemia gene. The parents are called carriers of the condition and have a 25 percent chance of having a child with TM. It is possible to screen for carriers of TM and use this information for pregnancy planning and management.

- TM is common among people from South and South East Asia and is an important public health concern in Singapore. More research is needed to explore the lives of people with TM, and the societal perceptions that exist in Singapore about TM.

Objectives:

- To describe the familial, social, and professional experiences of individuals with TM.

- To investigate the social messages being given out about TM in Singapore and the sources of those messages.

- To explore the impact of these experiences, perceptions, and social messages on individuals who have TM.

- To explore how the experiences and perceptions of individuals who have TM affect their life, sense of self, social integration, and compliance with medical treatment.

Eligibility:

- Residents of Singapore who are 14 years of age or older, can speak English, and currently have TM.

- Parents of individuals with TM who are 14 years of age or older. Parents must be 21 years of age or older, be able to speak English, and have had caregiving responsibilities for their child at some point.

Design:

- All participants will have a one-time semi-structured interview, followed by a questionnaire to obtain demographic information.

- Interviews will be conducted in Singapore and are expected to last for 30 to 90 minutes.

- Individuals with TM will be asked about their own perceptions of TM; familial, social, and professional experiences involving TM; and their perceptions of others views and of social messages related to TM.

- Parents of individuals with TM will be asked about their experiences in caring for a child with TM, talking to their child about TM, telling people about their child s TM, and interacting with health care providers.


Clinical Trial Description

Thalassemia major (TM) is a chronic, inherited hematological disorder that can require life-long medical care. As a result of the chronic and demanding nature of the condition, studies have shown that TM might negatively affect an individual s quality of life, sense of self, social integration, and compliance with medical treatment. Yet, little is known about affected individuals overall experiences with and perceptions of TM. In this study, the concept of stigma will be used to explore and understand these experiences and perceptions in the population of individuals with TM in Singapore. This study will involve qualitative interviews with TM patients and parents of TM patients. Interviews will focus on individuals family, social and professional experiences with TM; the social messages that exist in Singapore about TM and their sources; individuals perceptions of how others view TM; individuals own perceptions of TM; and the impact of these various experiences, messages and perceptions on the individual with TM. Interviews will be conducted with approximately 20-30 individuals with TM, and 10-20 parents of individuals with TM. Interviews will be transcribed and subjected to thematic analysis to identify common themes. The results of this study will further our understanding of the psychosocial burden of TM and the potential role of stigma in this population, which may ultimately inform the care for individuals with TM. The study s setting will also provide insights into the impact of the Singaporean sociocultural context on the psychosocial elements of living with a genetic condition, which might eventually help to inform the development of appropriate psychosocial support services and genetic counseling services in the region. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01129076
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase
Start date April 23, 2010
Completion date January 7, 2016

See also
  Status Clinical Trial Phase
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Recruiting NCT02126046 - Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major N/A
Completed NCT01125254 - Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Phase 2/Phase 3
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Completed NCT00733811 - Efficacy Study of the Use of Sequential DFP-DFO Versus DFP Phase 4
Enrolling by invitation NCT02986698 - In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) Phase 1
Not yet recruiting NCT06026839 - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
Terminated NCT00007072 - Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major Phase 2
Completed NCT04292314 - Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia Phase 2/Phase 3
Completed NCT02049450 - Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. Phase 2
Active, not recruiting NCT04523376 - Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies N/A
Completed NCT03992001 - Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients Phase 4
Not yet recruiting NCT05777733 - NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major Phase 1
Completed NCT01241357 - High-Tc Susceptometer to Monitor Transfusional Iron Overload Phase 2
Completed NCT00749515 - Pilot Study for Patients With Poor Response to Deferasirox Phase 4
Completed NCT04260516 - The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major Phase 1
Recruiting NCT02307786 - Long Term Outcomes in β Thalassemia Major N/A
Not yet recruiting NCT01323608 - The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Phase 4
Completed NCT00005893 - Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders N/A
Recruiting NCT06137079 - "Iron Overload and Endocrinological Diseases"